Technology | Treatment Planning | October 24, 2018

Siris Medical Releases PlanMD Decision Support Software

New software introduces real-time prescriptive contouring to enable faster, smarter radiation therapy treatment planning and better outcomes

Siris Medical Releases PlanMD Decision Support Software

October 24, 2018 — Siris Medical Inc. announced the release of its new artificial intelligence (AI) treatment decision-support system for use in radiation oncology. The new PlanMD software enables radiation oncology clinical teams to leverage patient data and artificial intelligence to efficiently empower their treatment decisions. The software is the first and only tool, according to the company, that enables the physician to see the effect of editing contours in real time, without re-optimizing or replanning.

PlanMD complements Siris Medical’s QuickMatch software, which accelerates the treatment planning process by using AI to quickly identify the most similar cases previously treated to inform planning decisions and help reduce dose to critical structures. Siris Medical President and CEO Colin Carpenter, Ph.D., said the software has been shown to enable clinical teams to save up to 70 percent of the time required to plan treatment.

This announcement follows a recent publication, “Clinical decision support of radiotherapy treatment planning: A data-driven machine learning strategy for patient-specific dosimetric decision making,” in the Journal of Radiotherapy and Oncology in December 2017.1 This study demonstrates the ability of the QuickMatch software to draw upon historical clinical insights for patient-specific decision making. The study was a collaborative effort between the University of California San Francisco (UCSF), University of Pennsylvania, University of Maryland and Siris Medical.

For more information: www.siris-medical.com

Reference

1. Valdes G., Simone C.B., Chen J., et al. Clinical decision support of radiotherapy treatment planning: A data-driven machine learning strategy for patient-specific dosimetric decision making. Journal of Radiotherapy and Oncology, Nov. 20, 2017. https://doi.org/10.1016/j.radonc.2017.10.014

Related Content

Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...
The research evaluates the feasibility of biology-guided radiotherapy to treat metastatic cancer
News | Radiation Therapy | October 24, 2020
October 24, 2020 — ...
AI-powered premium large bore CT scanner offers industry’s largest bore and widest field-of-view
News | Computed Tomography (CT) | October 24, 2020
October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S.
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...
IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy
News | Proton Therapy | October 23, 2020
October 23, 2020 — IBA, a leading provider of proton thera...